| |
Public Act 102-1039 Public Act 1039 102ND GENERAL ASSEMBLY |
Public Act 102-1039 | HB4556 Enrolled | LRB102 23790 CPF 33826 b |
|
| AN ACT concerning health.
| Be it enacted by the People of the State of Illinois,
| represented in the General Assembly:
| Section 5. The Overdose Prevention and Harm Reduction Act | is amended by changing Section 5 and by adding Section 10 as | follows: | (410 ILCS 710/5)
| Sec. 5. Needle and hypodermic syringe access program. | (a) Any governmental or nongovernmental organization, | including a local health department, community-based | organization, or a person or entity, that promotes | scientifically proven ways of mitigating health risks | associated with drug use and other high-risk behaviors may | establish and operate a needle and hypodermic syringe access | program. The objective of the program shall be accomplishing | all of the following: | (1) reducing the spread of HIV, AIDS, viral hepatitis, | and other bloodborne diseases; | (2) reducing the potential for needle stick injuries | from discarded contaminated equipment; and | (3) facilitating connections or linkages to | evidence-based treatment.
| (b) Programs established under this Act shall provide all |
| of the following: | (1) Disposal of used needles and hypodermic syringes. | (2) Needles, hypodermic syringes, and other safer drug | consumption supplies, at no cost and in quantities | sufficient to ensure that needles, hypodermic syringes, or | other supplies are not shared or reused. | (3) Educational materials or training on: | (A) overdose prevention and intervention; and | (B) the prevention of HIV, AIDS, viral hepatitis, | and other common bloodborne diseases resulting from | shared drug consumption equipment and supplies. | (4) Access to opioid antagonists approved for the | reversal of an opioid overdose, or referrals to programs | that provide access to opioid antagonists approved for the | reversal of an opioid overdose.
| (5) Linkages to needed services, including mental | health treatment, housing programs, substance use disorder | treatment, and other relevant community services. | (6) Individual consultations from a trained employee | tailored to individual needs. | (7) If feasible, a hygienic, separate space for | individuals who need to administer a prescribed injectable | medication that can also be used as a quiet space to gather | composure in the event of an adverse on-site incident, | such as a nonfatal overdose. | (8) If feasible, access to on-site drug adulterant |
| testing supplies such as reagents, test strips, or | quantification instruments that provide critical real-time | information on the composition of substances obtained for | consumption . | (c) Notwithstanding any provision of the Illinois | Controlled Substances Act, the Drug Paraphernalia Control Act, | or any other law, no employee or volunteer of or participant in | a program established under this Act shall be charged with or | prosecuted for possession of any of the following: | (1) Needles, hypodermic syringes, or other drug | consumption paraphernalia obtained from or returned, | directly or indirectly, to a program established under | this Act. | (2) Residual amounts of a controlled substance | contained in used needles, used hypodermic syringes, or | other used drug consumption paraphernalia obtained from or | returned, directly or indirectly, to a program established | under this Act. | (3) Drug adulterant testing supplies such as reagents, | test strips, or quantification instruments obtained from | or returned, directly or indirectly, to a program | established under this Act or a pharmacy, hospital, | clinic, or other health care facility or medical office | dispensing drug adulterant testing supplies in accordance | with Section 10. This paragraph also applies to any | employee or customer of a pharmacy, hospital, clinic, or |
| other health care facility or medical office dispensing | drug adulterant testing supplies in accordance with | Section 10 . | (4) Any residual amounts of controlled substances used | in the course of testing the controlled substance to | determine the chemical composition and potential threat of | the substances obtained for consumption that are obtained | from or returned, directly or indirectly, to a program | established under this Act.
This paragraph also applies to | any person using drug adulterant testing supplies procured | in accordance with Section 10 of this Act. | In addition to any other applicable immunity or limitation | on civil liability, a law enforcement officer who, acting on | good faith, arrests or charges a person who is thereafter | determined to be entitled to immunity from prosecution under | this subsection (c) shall not be subject to civil liability | for the arrest or filing of charges. | (d) Prior to the commencing of operations of a program | established under this Act, the governmental or | nongovernmental organization shall submit to the Illinois | Department of Public Health all of the following information: | (1) the name of the organization, agency, group, | person, or entity operating the program; | (2) the areas and populations to be served by the | program; and | (3) the methods by which the program will meet the |
| requirements of subsection (b) of this Section. | The Department of Public Health may adopt rules to | implement this subsection.
| (Source: P.A. 101-356, eff. 8-9-19.) | (410 ILCS 710/10 new) | Sec. 10. Dispensing of drug adulterant testing supplies. A | pharmacist, physician, advanced practice registered nurse, or | physician assistant, or the pharmacist's, physician's, | advanced practice registered nurse's, or physician assistant's | designee, may dispense drug adulterant testing supplies to any | person. Any drug adulterant testing supplies dispensed under | this Section must be stored at a licensed pharmacy, hospital, | clinic, or other health care facility or at the medical office | of a physician, advanced practice registered nurse, or | physician assistant and in a manner that limits access to the | drug adulterant testing supplies to pharmacists, physicians, | advanced practice registered nurses, or physician assistants | employed at the pharmacy, hospital, clinic, or other health | care facility or medical office and any persons designated by | the pharmacist, physician, advanced practice registered nurse, | or physician assistant. Drug adulterant testing supplies | dispensed at a retail store containing a pharmacy under this | Section may be dispensed only from the pharmacy department of | the retail store. No quantity of drug adulterant testing | supplies greater than necessary to conduct 5 assays of |
| substances suspected of containing adulterants shall be | dispensed in any single transaction.
| Section 99. Effective date. This Act takes effect upon | becoming law. |
Effective Date: 6/2/2022
|
|
|